By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ablynx 

Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


SEARCH JOBS








Company News
Ablynx (ABLYF) To Exercise Option To License Vectura (VEC.L)’s FOX Device For Use In Its Forthcoming Phase IIb Efficacy Study Of Its Inhaled Anti-RSV Nanobody (ALX-0171) 6/28/2016 11:42:20 AM
Ablynx (ABLYF) Release: Publication In Accordance With Article 15 Of The Belgian Law Of 2 May 2007 On The Publication Of Major Shareholdings (The "Transparency Law") 6/13/2016 7:40:43 AM
Ablynx (ABLYF) Reports Positive Top Line Results For Its Anti-RSV Nanobody (ALX-0171) Inhaled Using Vectura (VEC.L)’s FOX Device In A Phase I/IIa Study In Infants Hospitalized With RSV Infection 5/3/2016 9:09:07 AM
Ablynx (ABLYF) Announces 2015 Full Year Results 2/25/2016 9:42:08 AM
The New England Journal of Medicine Publishes Ablynx (ABLYF)’s Phase II TITAN Study Of Caplacizumab In Patients With Acquired TTP 2/11/2016 9:11:00 AM
Ablynx (ABLYF) To Receive €8 Million Milestone As Boehringer Ingelheim Starts First Patient Study With A Bi-Specific Nanobody In Oncology 1/29/2016 8:55:35 AM
Ablynx (ABLYF) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/7/2016 10:34:04 AM
Ablynx (ABLYF) Completes Enrolment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants 12/17/2015 10:22:01 AM
Ablynx (ABLYF) Appoints Robert K. Zeldin, MD, Chief Medical Officer 11/30/2015 11:16:25 AM
Ablynx (ABLYF), Novo Nordisk A/S (NVO) Ink Nanobody Pact Worth $399 Million+ 11/25/2015 10:07:32 AM
12345678910...
//-->